Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

Summary: Background: Staging and treatment of human African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT) required lumbar puncture to assess cerebrospinal fluid (CSF) and intravenous drugs that cross the blood–brain barrier for late-stage infection. These procedures are inconvenien...

Full description

Bibliographic Details
Main Authors: Victor Kande Betu Ku Mesu, DPH, Wilfried Mutombo Kalonji, MD, Clélia Bardonneau, MSc, Olaf Valverde Mordt, MSc, Digas Ngolo Tete, MPH, Séverine Blesson, MSc, François Simon, MSc, Sophie Delhomme, MSc, Sonja Bernhard, PhD, Hélène Mahenzi Mbembo, MD, Christian Mpia Moke, MD, Steven Lumeya Vuvu, MMed, Junior Mudji E'kitiak, MD, Felix Akwaso Masa, MD, Melchias Mukendi Ilunga, MD, Dieudonné Mpoyi Muamba Nzambi, MD, Tim Mayala Malu, MD, Serge Kapongo Tshilumbwa, MD, Franck Botalema Bolengi, MD, Mathieu Nkieri Matsho, MD, Crispin Lumbala, MPH, Bruno Scherrer, PhD, Nathalie Strub-Wourgaft, MD, Antoine Tarral, MD
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:The Lancet Global Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2214109X21002084

Internet

http://www.sciencedirect.com/science/article/pii/S2214109X21002084

Similar Items